Vinge is advising Danica Pension, Livsforsikringsaktieselskab, part of Danske Bank Group, in connection with the sale of all of shares in Danica Pension Försäkringsaktiebolag (publ).
Danica Pension Försäkringsaktiebolag (publ) has approx. 60 employees, 150,000 personal customers and 15,000 business customers.
Vinge advises Azelio in connection with its capital raising and listing on Nasdaq First North
Vinge has advised Azelio AB (publ) (“Azelio”) in connection with its capital raising and listing on Nasdaq First North.
Vinge advises Xspray Pharma in connection with a directed share issue
The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs.
Vinge advises in connection with the sale of school operations
Vinge has advised the sellers in connection with the sale of Kubikskolan AB to Læringsverkstedet.
Vinge advises Biotage in connection with its acquisition of PhyNexus
Vinge advises Biotage AB (publ) (“Biotage”), listed on Nasdaq Stockholm, in connection with its acquisition of PhyNexus, Inc. (“PhyNexus”), financed through a combination of newly issued shares and existing cash at hand.
Vinge assists Stendörren in connection with EQT Real Estate II’s cash offer to the shareholders in Stendörren
Vinge has assisted Stendörren Fastigheter AB (publ) (“Stendörren”) in connection with EQT Real Estate II’s, through Chicago Holding AB (“Chicago Holding”), cash offer to the shareholders in Stendörren.
Vinge advises Vicore Pharma in connection with a directed share issue
The board of directors of Vicore Pharma has resolved, subject to the approval by an extraordinary general meeting, on a directed new issue of shares, whereby Vicore Pharma will raise proceeds of approximately SEK 160 million before issue costs.
Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing
Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53.
Vinge has advised Swedish Airport Infrastructure in connection with a restructuring
Vinge has advised Swedavia Real Estate AB’s and Alecta pensionsförsäkring ömsesidigt’s jointly-owned joint venture company Swedish Airport Infrastructure KB and its subsidiary in connection with a restructuring of the group and a SEK 3.7 billion refinancing.
Vinge advises CELLINK in conjunction with the acquisition of Dispendix GmbH
Vinge has advised CELLINK AB, listed on First North Stockholm, in connection with the acquisition of all shares in Dispendix GmbH. Dispendix’s operations focus on bio dispensing technology and its patented technology emanates from a 10-year development within the German research institute Fraunhofer.
Vinge assists Vostok New Ventures Ltd in connection with an investment in Voi
Vinge has assisted Vostok New Ventures Ltd (“Vostok”) in connection with an investment by a number of investors in Voi Technology AB, a company that provides an electric scooter sharing service.
Blackrock has acquired the wind farm Enviksberget
Vinge has assisted Blackrock in its acquisition of the wind farm Enviksberget in Dalarna from Arise AB (publ).
Vinge advises Gotoga in conjunction with acquisition of Hope
Vinge has advised the newly-formed company Gotoga, where the ownership structure consists of the existing majority owner in Whyred, in conjunction with its acquisition of the Swedish parent company Hope
Vinge advised Equinor in connection with its investment in Medfield Diagnostics
Vinge advised Equinor Technology Ventures AS (”Equinor”) in connection with its acquisition in Medfield Diagnostics Aktiebolag (publ) (“Medfield”).